Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer: HCCSC G05 Trial

NCT04781686 is registered in ClinicalTrials.gov with Zhou Fuxiang as lead sponsor.

NCT NCT04781686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04781686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer: HCCSC G05 Trial
Lead sponsor
Zhou Fuxiang
Phase
Phase 2
Overall status
Unknown status
Start date
May 14, 2021
Completion date
August 31, 2025
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic gastric adenocarcinoma, metastatic gastroesophageal junction adenocarcinoma